A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation.
NIRF imaging
PSMA
extracellular vesicles
image-guided surgery
photodynamic therapy
prostate cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Oct 2022
25 Oct 2022
Historique:
received:
16
09
2022
revised:
10
10
2022
accepted:
19
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
A total of 20% to 50% of prostate cancer (PCa) patients leave the surgery room with positive tumour margins. The intraoperative combination of fluorescence guided surgery (FGS) and photodynamic therapy (PDT) may be very helpful for improving tumour margin delineation and cancer therapy. PSMA is a transmembrane protein overexpressed in 90−100% of PCa cells. The goal of this work is the development of a PSMA-targeted Near InfraRed Fluorescent probe to offer the surgeon a valuable intraoperative tool for allowing a complete tumour removal, implemented with the possibility of using PDT to kill the eventual not resected cancer cells. PSMA-617 binding motif was conjugated to IRDye700DX-NHS and the conjugation did not affect the photophysical characteristics of the fluorophore. The affinity of IRDye700DX-PSMA-617 towards PCa cells followed the order of their PSMA expression, i.e., PC3-PIP > LNCaP > PC3, PC3-FLU. NIRF imaging showed a significant PC3-PIP tumour uptake after the injection of 1 or 5 nmol with a maximum tumour-to-muscle ratio (ca. 60) observed for both doses 24 h post-injection. Importantly, urine, healthy prostate, and the bladder were not fluorescent at 24 h post-injection. Flow cytometry and confocal images highlighted a co-localization of PSMA+ cells with IRDye700DX-PSMA uptake. Very interestingly, ex vivo analysis on a tumour specimen highlighted a significant PSMA expression by tumour-associated macrophages, likely attributable to extracellular vesicles secreted by the PSMA(+) tumour cells. FGS proved that IRDye700DX-PSMA was able to easily delineate tumour margins. PDT experiments showed a concentration-dependent decrease in cell viability (from 75% at 10 nM to 12% at 500 nM), whereas controls did not show any cytotoxicity. PC3-PIP tumour-bearing mice subjected to photodynamic therapy showed a delayed tumour growth. In conclusion, a novel PSMA-targeted NIRF dye with dual imaging-PDT capabilities was synthesized and displayed superior specificity compared to other small PSMA targeted molecules.
Identifiants
pubmed: 36361667
pii: ijms232112878
doi: 10.3390/ijms232112878
pmc: PMC9657290
pii:
doi:
Substances chimiques
Antigens, Surface
0
Fluorescent Dyes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : 20124
Références
Theranostics. 2021 Jan 1;11(4):1527-1541
pubmed: 33408764
Cancers (Basel). 2022 Mar 23;14(7):
pubmed: 35406390
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Cancer Res. 2003 May 15;63(10):2645-8
pubmed: 12750292
Int J Oncol. 2010 Apr;36(4):777-84
pubmed: 20198319
J Photochem Photobiol B. 2021 Jun;219:112208
pubmed: 33989888
BMC Cancer. 2021 Mar 24;21(1):315
pubmed: 33761899
Theranostics. 2016 Apr 28;6(8):1085-95
pubmed: 27279903
Sci Rep. 2021 Jul 21;11(1):14925
pubmed: 34290365
Free Radic Biol Med. 2011 Aug 15;51(4):824-33
pubmed: 21664269
J Nucl Med. 2021 Feb;62(2):149-155
pubmed: 33443068
Cell Commun Signal. 2021 Nov 12;19(1):110
pubmed: 34772427
Photochem Photobiol. 1997 Mar;65(3):422-6
pubmed: 9077123
Urology. 2007 Aug;70(2):385-90
pubmed: 17826525
J Clin Invest. 2016 Apr 1;126(4):1144-51
pubmed: 27035806
J Nucl Med. 2019 Jan;60(1):71-78
pubmed: 30237214
J Med Chem. 2016 Mar 10;59(5):1761-75
pubmed: 26878194
Bioconjug Chem. 2018 Nov 21;29(11):3746-3756
pubmed: 30350576
J Nucl Med. 2020 Jan;61(1):13-19
pubmed: 31712326
Biomedicines. 2021 Apr 03;9(4):
pubmed: 33916774
Br J Cancer. 2022 Feb;126(3):331-350
pubmed: 34811504
Prostate. 2019 Dec;79(16):1832-1836
pubmed: 31553506
Prostate. 2012 Apr;72(5):523-32
pubmed: 21748756
Eur Urol. 2022 Jan;81(1):5-33
pubmed: 34489140
Methods Enzymol. 2000;319:376-400
pubmed: 10907528
J Nucl Med. 2020 Jan;61(1):6-12
pubmed: 31732677
PLoS One. 2014 Oct 03;9(10):e109427
pubmed: 25279468
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
Mol Imaging Biol. 2020 Feb;22(1):85-93
pubmed: 31025163
Theranostics. 2015 Jan 01;5(3):289-301
pubmed: 25553116
Immunology. 2013 Feb;138(2):93-104
pubmed: 23113570
Nat Rev Urol. 2016 Apr;13(4):226-35
pubmed: 26902337
J Nucl Med. 2015 Sep;56(9):1401-1407
pubmed: 26182968
Cancer Res. 1999 Jul 1;59(13):3192-8
pubmed: 10397265
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2425-2435
pubmed: 35029739
Photoacoustics. 2018 Aug 03;11:36-45
pubmed: 30105205
Cancers (Basel). 2020 Jan 27;12(2):
pubmed: 32012717
Theranostics. 2019 May 4;9(10):2924-2938
pubmed: 31244933
J Extracell Vesicles. 2021 Aug;10(10):e12136
pubmed: 34434533
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):11-26
pubmed: 34050265
Theranostics. 2021 Aug 26;11(18):9054-9088
pubmed: 34522227
Clin Cancer Res. 2019 Jan 1;25(1):177-187
pubmed: 30201762
Urology. 2001 Apr;57(4):801-5
pubmed: 11306418
Mol Cancer Ther. 2016 Aug;15(8):1834-44
pubmed: 27297866
Cancer Res. 2020 Jan 15;80(2):156-162
pubmed: 31719100
Curr Med Chem. 2012;19(6):856-70
pubmed: 22214450
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
Int J Mol Sci. 2022 Jan 21;23(3):
pubmed: 35163083
Prostate Cancer. 2011;2011:673021
pubmed: 22110996
Front Oncol. 2021 Nov 17;11:738323
pubmed: 34868932
Mol Cancer Ther. 2016 Jan;15(1):106-113
pubmed: 26586724
Cells. 2021 Oct 29;10(11):
pubmed: 34831170
J Med Chem. 2009 Jan 22;52(2):347-57
pubmed: 19111054
Theranostics. 2022 Feb 21;12(5):2335-2350
pubmed: 35265213
J Photochem Photobiol B. 2017 Feb;167:111-116
pubmed: 28063300
J Nucl Med. 2015 Jun;56(6):914-20
pubmed: 25883127
Cancers (Basel). 2021 Dec 21;14(1):
pubmed: 35008178
Theranostics. 2019 Sep 20;9(23):6824-6839
pubmed: 31660071
Br J Radiol. 2018 Nov;91(1091):20170893
pubmed: 29565650